Vanda Pharmaceuticals (VNDA) Return on Capital Employed Growth (5y) (2016 - 2026)

Vanda Pharmaceuticals (VNDA) Return on Capital Employed Growth (5y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,200.25 Bn 66,199.96 Bn -
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 471.75 Bn 466.96 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.94 Bn 114.69 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.87 Bn 61.12 Bn 3.31 Bn
7 Belite Bio 62.43 Bn 62.43 Bn -
8 Argenx Se 55.86 Bn 50.68 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn
10 Vanda Pharmaceuticals 314.84 Mn 112.53 Mn 48.56 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -5,716.00
Dec 31, 2025 -4,374.00
Sep 30, 2025 -2,913.00
Jun 30, 2025 -2,541.00
Mar 31, 2025 -1,922.00
Dec 31, 2024 -1,282.00
Sep 30, 2024 -1,433.00
Jun 30, 2024 -1,357.00
Mar 31, 2024 -1,062.00
Dec 31, 2023 -1,058.00
Sep 30, 2023 -404.00
Jun 30, 2023 201.00
Mar 31, 2023 639.00
Dec 31, 2022 1,368.00
Sep 30, 2022 1,287.00
Jun 30, 2022 1,136.00
Mar 31, 2022 1,516.00
Dec 31, 2021 1,990.00
Sep 30, 2021 2,999.00
Jun 30, 2021 3,578.00